Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Intensity Modulated Radiotherapy Dose Escalation Trial for Prostate Cancer Using Hypofractionation

NCT00062309 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT00062309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00062309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Intensity Modulated Radiotherapy Dose Escalation Trial for Prostate Cancer Using Hypofractionation
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2002
Completion date
Not reported
Enrollment
307 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer